

Germany Insulin Drugs And Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

Report description:

The Germany Insulin Drugs And Delivery Devices Market size is estimated at USD 1.10 billion in 2024, and is expected to reach USD 1.13 billion by 2029, growing at a CAGR of 0.5% during the forecast period (2024-2029).

One of the most significant risk factors for a severe course of COVID-19 is diabetes mellitus. This risk is believed to be influenced by several variables that are frequently present in diabetes mellitus, such as advanced age, a proinflammatory and hypercoagulable condition, hyperglycemia, and underlying comorbidities (hypertension, cardiovascular disease, chronic kidney disease, and obesity). Diabetes was quickly recognized as a risk factor for bad results during the COVID-19 pandemic. That's why managing or delaying cases of type 2 diabetes became more important than ever before. Several studies have confirmed that chronic diseases like diabetes are associated with adverse outcomes in COVID-19 patients.

Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and, thus, incur more healthcare expenses compared to non-diabetic people. People with diabetes face a higher chance of experiencing serious complications from COVID-19. In general, people with diabetes are more likely to experience severe symptoms and complications when infected with a virus. Diabetes and high glucose levels are associated with increased complications, respiratory failure, and mortality in hospitalized patients with coronavirus.

Germany is one of the developed countries and advanced in terms of healthcare facilities. Technologies, such as continuous glucose monitoring and insulin infusion pumps, are getting more adopted rapidly in Germany than the other developing countries. Moreover, the reimbursement policy and the pricing policy are highly regulated, which drives the market and increases the adoption rate of new and advanced technologies. The pandemic also highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care, through virtual consultations between healthcare providers and people with diabetes,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

and the use of diabetes technology. Crisis management has created unprecedented interest in remote care from both patients and providers and removed many long-standing regulatory barriers. Thus, the COVID-19 outbreak increased the insulin market's growth.

Germany Insulin Drugs And Delivery Devices Market Trends

Rising diabetes prevalence

In Germany, the diabetes population is expected to increase with a CAGR greater than 0.48% over the forecast period.

According to the German Diabetes Centre (DDZ) 2022, about 8.5 million people in Germany are affected by diabetes. The number of people with type 2 diabetes in Germany will continue to increase over the next twenty years. Researchers at DDZ estimate that up to twelve million people might suffer from metabolic disorders in 2040. Germany is one of the developed countries and advanced healthcare facilities. Technologies, such as continuous glucose monitoring and insulin infusion pumps, are getting more rapidly adopted in Germany than the other developing countries. Moreover, the reimbursement and pricing policies are highly regulated, facilitating the adoption rate of new and advanced technologies.

German law requires public plans to cap out-of-pocket health care costs and to cover all medically necessary treatment, including insulin drugs. German diabetes patients have some of the lowest out-of-pocket costs in the world, according to T1 International, an advocacy group for people with diabetes. Stringent government policies and favorable regulations by WHO in Germany are encouraging companies to develop innovative products. Penetration of these products in the German market supports local clinical research organizations in their clinical research trials and ensures ease of management, facilitating the discovery process. Leading manufacturers focus on technological innovations and develop advanced products to gain a substantial market share. There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps. Technological innovations and advancements offer many conveniences in maintaining blood glucose levels.

Therefore, owing to the increasing diabetes prevalence, the studied market is anticipated to grow over the analysis period.

The insulin pumps segment is expected to witness the highest growth rate over the forecast period

The insulin pumps segment holds a major market share in the insulin delivery devices market in the current year and is expected to grow with a CAGR of about 2.7% in the market over the forecast period because of the increasing technological advancement and its preference over other traditional methods due to continuous insulin administration.

An insulin pump is a device that delivers insulin continuously or, whenever required, automatically. The pump mimics the human pancreas. The insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen. Insulin pump therapy is a well-established insulin administration method for T1DM people. Pumps are a validated, time-tested therapeutic option in T1DM at all ages, enabling near-physiological insulin delivery in situations where the pancreas does not produce insulin. There are even pump models with remote controls enabling parents of young children to either suspend or bolus insulin from a distance when the child is playing or eating. The insulin infusion pumps reduce the large swings in blood glucose levels, induce less pain, and deliver more accurately when compared to injections. These advantages of insulin pumps over the traditional delivery system are expected to boost the market.

The frequency of monitoring glucose levels depends on the type of diabetes, which varies from patient to patient. Type-1 diabetic patients must check their blood glucose levels regularly, monitor their blood glucose levels, and adjust the insulin dosing accordingly, likely to drive segment growth during the forecast period. Continuous subcutaneous insulin infusion and continuous glucose monitoring systems have improved patient care and quality of life and are widely used in the ambulatory setting.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Increasingly, this technology is also being used in the hospital setting.

Germany Insulin Drugs And Delivery Devices Industry Overview

The Germany Insulin Drugs and Delivery Devices Market is moderately consolidated, with few significant and generic players. Mergers and acquisitions between the players recently have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance in developing and commercializing Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.

Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Table of Contents:

1 INTRODUCTION

- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
- 4.4 Porter's Five Forces Analysis
 - 4.4.1 Bargaining Power of Suppliers
 - 4.4.2 Bargaining Power of Consumers
 - 4.4.3 Threat of New Entrants
 - 4.4.4 Threat of Substitute Products and Services
 - 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

- 5.1 Drug
 - 5.1.1 Basal or Long-acting Insulins
 - 5.1.1.1 Lantus (Insulin Glargine)
 - 5.1.1.2 Levemir (Insulin Detemir)
 - 5.1.1.3 Toujeo (Insulin Glargine)
 - 5.1.1.4 Tresiba (Insulin Degludec)
 - 5.1.1.5 Basaglar (Insulin Glargine)
 - 5.1.1.5.1 Other drugs
 - 5.1.2 Bolus or Fast-acting Insulins
 - 5.1.2.1 NovoRapid/Novolog (Insulin aspart)
 - 5.1.2.2 Humalog (Insulin lispro)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1.2.3 Apidra (Insulin glulisine)
- 5.1.2.4 FIASP (Insulin aspart)
- 5.1.2.5 Admelog (Insulin lispro Sanofi)
- 5.1.3 Traditional Human Insulins
 - 5.1.3.1 Novolin/Mixtard/Actrapid/Insulatard
 - 5.1.3.2 Humulin
 - 5.1.3.3 Insuman
- 5.1.4 Combination Insulins
 - 5.1.4.1 NovoMix (Biphasic Insulin aspart)
 - 5.1.4.2 Ryzodeg (Insulin degludec and Insulin aspart)
 - 5.1.4.3 Xultophy (Insulin degludec and Liraglutide)
 - 5.1.4.4 Soliqua/Suliqua (Insulin glargine and Lixisenatide)
- 5.1.5 Biosimilar Insulins
 - 5.1.5.1 Insulin Glargine Biosimilars
 - 5.1.5.2 Human Insulin Biosimilars
- 5.2 Device
 - 5.2.1 Insulin Pumps
 - 5.2.1.1 Insulin Pump Devices
 - 5.2.1.2 Insulin Pump Reservoirs
 - 5.2.1.3 Insulin Infusion sets
 - 5.2.2 Insulin Pens
 - 5.2.2.1 Cartridges in reusable pens
 - 5.2.2.2 Disposable insulin pens
 - 5.2.3 Insulin Syringes
 - 5.2.4 Insulin Jet Injectors

6 MARKET INDICATORS

- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population

7 COMPETITIVE LANDSCAPE

7.1 COMPANY PROFILES

- 7.1.1 Novo Nordisk
- 7.1.2 Sanofi
- 7.1.3 Eli Lilly
- 7.1.4 Biocon
- 7.1.5 Julphar
- 7.1.6 Medtronic
- 7.1.7 Ypsomed
- 7.1.8 Becton Dickinson

7.2 COMPANY SHARE ANALYSIS

- 7.2.1 Insulin Drugs
 - 7.2.1.1 Novo Nordisk
 - 7.2.1.2 Sanofi
 - 7.2.1.3 Eli Lilly
- 7.2.2 Insulin Delivery Devices
 - 7.2.2.1 Medtronic

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.2.2.2 Ypsomed

7.2.2.3 Becton Dickinson

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Germany Insulin Drugs And Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-06"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com